AnaptysBio (ANAB) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ANAB Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

AnaptysBio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ANAB Stock 12 Month Forecast

Average Price Target

$1,410.40

▲(111.14% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for AnaptysBio in the last 3 months. The average price target is $1,410.40 with a high forecast of $1,661.01 and a low forecast of $1,223.90. The average price target represents a 111.14% change from the last price of $668.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"518":"$518","804":"$804","1090":"$1,090","1376":"$1,376","1662":"$1,662"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1661.01339345,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.66K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1410.40435514,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.41K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1223.9046057,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.22K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[518,804,1090,1376,1662],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,668,744.38564565,820.7712913,897.15693695,973.5425826000001,1049.92822825,1126.3138739,1202.6995195499999,1279.0851652000001,1355.47081085,1431.8564565000001,1508.24210215,1584.6277478,{"y":1661.01339345,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,668,725.1080273184615,782.2160546369231,839.3240819553846,896.4321092738462,953.5401365923077,1010.6481639107692,1067.7561912292308,1124.8642185476924,1181.9722458661538,1239.0802731846154,1296.1883005030768,1353.2963278215384,{"y":1410.40435514,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,668,710.7618927461539,753.5237854923078,796.2856782384615,839.0475709846154,881.8094637307693,924.571356476923,967.3332492230769,1010.0951419692308,1052.8570347153845,1095.6189274615385,1138.3808202076923,1181.142712953846,{"y":1223.9046057,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":580,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":519.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":519.14,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":580,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":580,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 47, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 46, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 103, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 123, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 101, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 47, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,661

Average Price Target$1,410

Lowest Price Target$1,224

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Etzer Darout

Barclays

$1,311.33

Buy

96.31%

Upside

Reiterated

07/23/26

Analysts Offer Insights on Healthcare Companies: Community Health (NYSE: CYH), AnaptysBio (NASDAQ: ANAB) and Repligen (NASDAQ: RGEN)

Yasmeen Rahimi

Piper Sandler

$1,626.04

Buy

143.42%

Upside

Reiterated

07/21/26

Joseph Pantginis

H.C. Wainwright

$1,661.01

Buy

148.65%

Upside

Reiterated

07/21/26

Buy Rating Reaffirmed on Litigation Clarity and Asset Value; $95 Price Target Maintained

Joseph Thome

TD Cowen

$1,311.33

Buy

96.31%

Upside

Reiterated

07/13/26

TD Cowen Remains a Buy on AnaptysBio (ANAB)

Michael Yee

UBS

$1,328.81

Buy

98.92%

Upside

Reiterated

06/30/26

Analysts Are Bullish on Top Healthcare Stocks: MindWalk Holdings (HYFT), AnaptysBio (ANAB)

David Risinger

Leerink Partners

―

Buy

―

Reiterated

05/27/26

Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), GeoVax Labs (NASDAQ: GOVX) and Vir Biotechnology (NASDAQ: VIR)

Anupam Rama

J.P. Morgan

$1,206.42→$1,223.9

Buy

83.22%

Upside

Reiterated

05/22/26

J.P. Morgan Sticks to Its Buy Rating for AnaptysBio (ANAB)

David Nierengarten

Wedbush

$1,049.06→$1,311.33

Buy

96.31%

Upside

Reiterated

03/31/26

Wedbush Remains a Buy on AnaptysBio (ANAB)

Joon Lee

Truist Financial

$629.44→$874.22

Hold

30.87%

Upside

Reiterated

03/09/26

Truist Financial Keeps Their Hold Rating on AnaptysBio (ANAB)

Alex Thompson CFA

Stifel Nicolaus

$979.12→$1,486.17

Buy

122.48%

Upside

Reiterated

03/05/26

Analysts Are Bullish on These Healthcare Stocks: Veeva Systems (VEEV), Apellis Pharmaceuticals (APLS)

Yatin Suneja

Guggenheim

$2,447.81

Buy

266.44%

Upside

Reiterated

03/04/26

Guggenheim Reaffirms Their Buy Rating on AnaptysBio (ANAB)

Derek Archila

Wells Fargo

$1,416.23

Buy

112.01%

Upside

Reiterated

12/16/25

AnaptysBio (ANAB) Receives a Buy from Wells Fargo

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Etzer Darout

Barclays

$1,311.33

Buy

96.31%

Upside

Reiterated

07/23/26

Analysts Offer Insights on Healthcare Companies: Community Health (NYSE: CYH), AnaptysBio (NASDAQ: ANAB) and Repligen (NASDAQ: RGEN)

Yasmeen Rahimi

Piper Sandler

$1,626.04

Buy

143.42%

Upside

Reiterated

07/21/26

Joseph Pantginis

H.C. Wainwright

$1,661.01

Buy

148.65%

Upside

Reiterated

07/21/26

Buy Rating Reaffirmed on Litigation Clarity and Asset Value; $95 Price Target Maintained

Joseph Thome

TD Cowen

$1,311.33

Buy

96.31%

Upside

Reiterated

07/13/26

TD Cowen Remains a Buy on AnaptysBio (ANAB)

Michael Yee

UBS

$1,328.81

Buy

98.92%

Upside

Reiterated

06/30/26

Analysts Are Bullish on Top Healthcare Stocks: MindWalk Holdings (HYFT), AnaptysBio (ANAB)

David Risinger

Leerink Partners

―

Buy

―

Reiterated

05/27/26

Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), GeoVax Labs (NASDAQ: GOVX) and Vir Biotechnology (NASDAQ: VIR)

Anupam Rama

J.P. Morgan

$1,206.42→$1,223.9

Buy

83.22%

Upside

Reiterated

05/22/26

J.P. Morgan Sticks to Its Buy Rating for AnaptysBio (ANAB)

David Nierengarten

Wedbush

$1,049.06→$1,311.33

Buy

96.31%

Upside

Reiterated

03/31/26

Wedbush Remains a Buy on AnaptysBio (ANAB)

Joon Lee

Truist Financial

$629.44→$874.22

Hold

30.87%

Upside

Reiterated

03/09/26

Truist Financial Keeps Their Hold Rating on AnaptysBio (ANAB)

Alex Thompson CFA

Stifel Nicolaus

$979.12→$1,486.17

Buy

122.48%

Upside

Reiterated

03/05/26

Analysts Are Bullish on These Healthcare Stocks: Veeva Systems (VEEV), Apellis Pharmaceuticals (APLS)

Yatin Suneja

Guggenheim

$2,447.81

Buy

266.44%

Upside

Reiterated

03/04/26

Guggenheim Reaffirms Their Buy Rating on AnaptysBio (ANAB)

Derek Archila

Wells Fargo

$1,416.23

Buy

112.01%

Upside

Reiterated

12/16/25

AnaptysBio (ANAB) Receives a Buy from Wells Fargo

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AnaptysBio

3 Months

Joseph ThomeTD Cowen

Success Rate

13/20 ratings generated profit

Average Return

+15.05%

reiterated a buy rating 17 days ago

Copying Joseph Thome's trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +15.05% per trade.

1 Year

Anupam RamaJ.P. Morgan

Success Rate

14/18 ratings generated profit

Average Return

+98.96%

reiterated a buy rating 2 months ago

Copying Anupam Rama's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +98.96% per trade.

2 Years

Derek ArchilaWells Fargo

Success Rate

13/13 ratings generated profit

Average Return

+253.06%

reiterated a buy rating 8 months ago

Copying Derek Archila's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +253.06% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ANAB Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

103

123

101

Sell

Strong Sell

total

138

180

159

In the current month, ANAB has received 52 Buy Ratings, 47 Hold Ratings, and 0 Sell Ratings. ANAB average Analyst price target in the past 3 months is 1,410.40.

Each month's total comprises the sum of three months' worth of ratings.

ANAB Financial Forecast

ANAB Earnings Forecast

Next quarter’s earnings estimate for ANAB is -$2.18 with a range of -$14.65 to $5.86. The previous quarter’s EPS was -$32.10. ANAB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 40.44% of the time in the same period. In the last calendar year ANAB has Performed in-line its overall industry.

ANAB Sales Forecast

Next quarter’s sales forecast for ANAB is $302.36M with a range of $0.00 to $645.40M. The previous quarter’s sales results were $445.78M. ANAB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 39.52% of the time in the same period. In the last calendar year ANAB has Performed in-line its overall industry.

ANAB Stock Forecast FAQ

What is MX:ANAB’s average 12-month price target, according to analysts?

Based on analyst ratings, AnaptysBio’s 12-month average price target is 1,410.40.

What is MX:ANAB’s upside potential, based on the analysts’ average price target?

AnaptysBio has 111.14% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AnaptysBio a Buy, Sell or Hold?

AnaptysBio has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is AnaptysBio’s share price target?

The average share price target for AnaptysBio is 1,410.40. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $1,661.01 ,and the lowest forecast is $1,223.90. The average share price target represents 111.14% Increase from the current price of $668.

What do analysts say about AnaptysBio?

AnaptysBio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of AnaptysBio?

To buy shares of MX:ANAB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AnaptysBio (ANAB) Stock Forecast & Price Target

ANAB Analyst Ratings

ANAB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AnaptysBio

ANAB Analyst Recommendation Trends

ANAB Financial Forecast

ANAB Earnings Forecast

ANAB Sales Forecast

ANAB Stock Forecast FAQ

Detailed List of Analyst Forecasts